LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

3 result(s)
Filter and sort
3 result(s)
Journal Article > CommentaryFull Text

Oops, what about ethics?

Public Health Action. 21 September 2013; Volume 3 (Issue 3); 253-4.; DOI:10.5588/pha.13.0029
Oladimeji O, Isaakidis P, Zachariah R, Hinderaker SG, Koghali M,  et al.
Public Health Action. 21 September 2013; Volume 3 (Issue 3); 253-4.; DOI:10.5588/pha.13.0029
Ethics approval of research studies is essential for the protection and rights of study subjects, whether this is for prospective research or record reviews. This article shares a painful lesson learned from a field experience where the appropriate steps for obtaining ethics approval were not followed by a young researcher. This researcher had embarked on an operational research project, but had omitted to seek ethics approval from a local ethics committee. Young researchers, particularly from low- and middle-income countries, need to learn about the importance and value of ethics. More
Journal Article > ResearchFull Text

Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria

PLOS One. 17 March 2015; Volume 10 (Issue 3); DOI:10.1371/journal.pone.0120161
Avong YK, Isaakidis P, Hinderaker SG, Van der Bergh R, Ali E,  et al.
PLOS One. 17 March 2015; Volume 10 (Issue 3); DOI:10.1371/journal.pone.0120161
Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria.More
Journal Article > ResearchFull Text

Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria

PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali MA,  et al.
PLOS One. 10 April 2014; Volume 9 (Issue 4); DOI:10.1371/journal.pone.0094393
Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.More